Key Decisions in HIV Care: Switching to a 2-Drug Single-Tablet Regimen

In this episode, William R. Short, MD, MPH, AAHIVS, explores recommendations and data on switching to 2-drug single-tablet ART regimens.

Listen as he gives his perspectives on:

• Indications for the available 2-drug single-tablet regimens: DTG/RPV and DTG/3TC
• The SWORD-1 and SWORD-2 studies evaluating switching to DTG/RPV in virologically suppressed patients
• Real-world experience with switching to DTG/RPV from the OPERA study
• The TANGO study evaluating switching to DTG/3TC from a stable TAF-based ART regimen
• The SALSA study evaluating switching to DTG/3TC from any stable 3-drug ART regimen

Presenter:
William R. Short, MD, MPH, AAHIVS
Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

Follow along with the slides at:
https://bit.ly/3n0Z8wU

See the entire program at:
https://bit.ly/2TXTYWx